MS4A1 (Membrane Spanning 4-Domains A1)

We developed and validated an immune-related signature for predicting TNBC outcomes and immunotherapy response. This signature reflects underlying immune landscape heterogeneity and provides a crucial method for patient stratification and immunotherapeutic planning.

Together, this study provides a systems-level framework linking transcriptional with survival outcomes. By combining established immune checkpoints with novel candidates, our findings expand the biomarker landscape for prognostic stratification and therapeutic targeting in lung cancer.

This study identified three LUAD subtypes with distinct immune characteristics and constructed a seven-gene prognostic model. This model correlates with immune checkpoint and chemotherapy sensitivity, providing new targets and strategies for clinical diagnosis and treatment.

High SIGLEC8 expression predicts longer survival in SKCM. We propose that SIGLEC8 boosts antitumor immunity by influencing B‑cell and T‑cell pathways (including FCER2, CR2, MS4A1, and CD8A/B) in the tumor microenvironment. SIGLEC8 thus shows promise as a low‑cost prognostic biomarker and a potential therapeutic target. Table S1 shows cancer-type-specific prognostic effects for SIGLEC8: in SKCM higher SIGLEC8 expression associates with improved survival, whereas prognostic directionality varies across other tumor types. A pan-cancer comparison revealed cancer-type-specific prognostic effects for SIGLEC8: in SKCM higher SIGLEC8 expression associates with improved survival, whereas prognostic directionality varies across other tumor types.

We found a significant inverse association between smudge cells and both surface CD20 and soluble CD20/MS4A1 in our study examining the correlation between smudge cells, soluble CD20, and CD20/MS4A1 in CLL patients. Our findings indicate that soluble CD20 may contribute to understanding the pathophysiology of smudge cells and could be further investigated as a potential prognostic marker in CLL.

Their involvement in BCR and PI3K-AKT pathways underscores novel vulnerabilities for overcoming refractory disease. Our findings provide a foundation for developing strategies to improve outcomes in high-risk DLBCL patients with hypoxic microenvironments.

In vivo experiments also demonstrated that verteporfin inhibited the in-situ tumor progression and ivonescimab enhanced the efficacy of immunotherapy in MS4A1 low tumor-bearing mouse. The MS4A1/M1 macrophage axis was identified as a crucial regulator of malignancy in LUAD, indicating MS4A1 as a promising novel therapeutic target for advanced LUAD treatment.

Ultimately, through the validation of clinical samples and the analysis of prognostic characteristics, three genes were confirmed to be reduced in AML patients, and their high expression suggested a favorable prognosis. Our study identified and validated the efficacy of SLC16A6, CCR7, and MS4A1 as tumor suppressors implicated in AML progression and related to immune cell infiltration.

Treatment with rituximab depletes this population, suggesting potential therapeutic implications. Our findings establish CD20+ NK cells as a functionally distinct lymphocyte subset with enhanced effector capabilities and tissue-homing properties, providing new insights into immune regulation in inflammatory diseases.

This highlights the importance of including diverse populations in studies of genetic associations and suggests that multiple pathways may lead to strabismus in different population groups. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

MS4A12 expression may offer a helpful predictive and prognostic indicator for identifying patients who could gain advantages from neoadjuvant CCRT.

All three macrophage markers correlated positively with Ann Arbor stage, indicating their potential involvement in the dissemination of cHL in general. Our findings suggest a potential role for tumor-associated macrophages in the dissemination of cHL to bone.